Meridian Bioscience Inc

Meridian Bioscience — FY2018 Earnings Presentation

29 slides from Meridian Bioscience's earnings presentation, Nov 8, 2018

  1. Slide 1: Fourth Quarter and Full Year Fiscal 2018 Results

    Fourth Quarter and Full Year Fiscal 2018 Results November 8, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the m

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of restructuring costs, litigation costs, goodwill impairment charge, and certain one-

  4. Slide 4: Agenda

    Agenda Company Highlights – Jack Kenny, CEO Financial Results & Guidance – Melissa Lueke, CFO Strategy Overview – Jack Kenny, CEO Q&A

  5. Slide 5: Company Highlights

    Company Highlights Consolidated separately-run companies into 2 global business units Completed re-alignment of organizational structure Stronger, more sustainable organization positioned for growth Cost efficiencies to support growth re-investment Launched new branding Entered into a strategic coll

  6. Slide 6: 2018 Fiscal Fourth Quarter Earnings Summary

    2018 Fiscal Fourth Quarter Earnings Summary($000’s except Per Share Amounts) Adjusted (Non-GAAP) 2018 2017Change Revenue$53,100$49,697+6.8% Gross Margin60.5%61.6%-1.1 pts Operating expenses Ratio$20,464 38.5%$21,061 42.4%-2.8%-3.9 pts Operating income Margin $11,686 22.0%$9,569 19.3%+22.1%2.7 pts Ne

  7. Slide 7: 2018 Fiscal Fourth Quarter Operating Segment Highlights

    2018 Fiscal Fourth QuarterOperating Segment Highlights ($000’s) Diagnostics 2018 2017Change Revenue$36,814$35,992+2.3% Operating income (Non-GAAP)% Margin$6,77518.4% $6,69618.6% +1.2%-0.2 pts Revenue by: Technology: Molecular assays Immunoassays & blood chemistry Disease State: GI (Gastrointestinal)

  8. Slide 8: 2018 Fiscal Full Year Earnings Summary

    2018 Fiscal Full Year Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) 2018 2017Change Revenue $213,571 $200,771+6.4% Margin 61.1% 61.9%-0.8 pts Operating expenses Ratio $85,826 40.2% $79,520 39.6% +7.9% +0.6 pts Operating income Margin $44,635 20.9% $44,772 22.3% -0.3% -1.4 pt

  9. Slide 9: 2018 Fiscal Full Year Operating Segment Highlights

    2018 Fiscal Full YearOperating Segment Highlights ($000’s) Diagnostics 2018 2017Change Revenue$150,454$143,521+4.8% Operating income (Non-GAAP) (1) % Margin$29,701 19.7%$30,476 21.2%-2.5%-1.5 pts Revenue by: Technology: Molecular assays Immunoassays & blood chemistry Disease State: GI (Gastrointesti

  10. Slide 10: 2019 Fiscal Year Guidance

    2019 Fiscal Year Guidance Consolidated net revenues 2%-4% growth Operating margin ~20% Tax rate 25.5% Earnings per Share $0.74-$0.76 Diagnostics Net revenues low single-digit growth Operating margin down 0-50 bps year-over-year Life Science Net revenues low double-digit growth Operating margin conti

  11. Slide 11: Company Strategy Overview

    Company Strategy Overview ~

  12. Slide 12: Increasing and new regulatory market obstacles Pricing pressure due to reimbursement changes IDN and

    Increasing and new regulatory market obstacles Pricing pressure due to reimbursement changes IDN and customer Consolidation Continued growth and shift to molecular testing China as a growth market opportunity 12

  13. Slide 13: Key Elements of Company Strategy

    Key Elements of Company Strategy Growth orientation Re-shape the Focus and concentrate resources on core financial profile Address areas of vulnerability Focused, new Organic and inorganic investment to Jump start R&D, accelerate pipeline support growth Proactive and programmatic M&A Consolidate & r

  14. Slide 14: Capital Allocation

    Capital Allocation Meridian Capital Deployed Strong track record of returning capital to shareholders Company regularly evaluates its capital allocation priorities Continued commitment to distributing excess capital to shareholders through regular dividends and other means Imminent opportunities to

  15. Slide 15: Diagnostics Strategy

    Diagnostics Strategy ~

  16. Slide 16: The Changing Healthcare Market

    The Changing Healthcare Market Market Trends Shift to value-based reimbursement Increasing cost pressure Growing chronic disease burden Staff shortage Consumerism Population growth Demographic shift Rapid scientific progress Market Impact Consolidation Building the critical mass StandardizationOpera

  17. Slide 17: Market Impact: Consolidation of IDNs

    Market Impact Consolidation of IDNs Consolidation of healthcare systems diversifying their businesses both vertically and horizontally USA 2014 USA 2024 Only 50% of current health systems will likely remain Source: Deloitte Center for Health Solutions. (2014). The great consolidation: The potential

  18. Slide 18: Vision

    Vision The health system’s (IDNs) trusted partner, spanning the continuum of care from the physician office to the hospital laboratory, delivering expertise and innovation in gastrointestinal disease testing and supporting the well-being of our children to improve health outcomes and build a healthi

  19. Slide 19: Platform and Menu Positioning

    Platform and Menu Positioning Platform Designs Curian (IA) An analyzer to take technical errors and guesswork out of rapid testing MDx Platform Investment • Improved workflow, smaller footprint, and easier sample prep • 2-4 color channel capabilities • Easy to manage and onboard GUI • Low maintenanc

  20. Slide 20: Platform and Menu Positioning

    Platform and Menu Positioning Platform Design POC design IN DEVELOPMENT 1. CLIA-waivable 2. Rapid results 3. Low cost instrument 4. Versatile instrument with a small footprint 5. Room temperature storage 6. High volume pediatric Dx tests Continue to focus and LeadCare and penetrate pediatric POLs Ne

  21. Slide 21: Meridian's Current and Expanded Market Opportunities (U.S.)

    Meridian’s Current (Dark) and Expanded (Light) Market Opportunities (U.S.) Lab Revenues: Sites: $21B 5,900 $32B 8,900 $3B 120,000 (11,700 CLIA) Independent Labs Large Hospitals Medium Hospitals Small Hospitals Physician Office Labs Immunoassay DiaSorin Automated HpSA ELISA HpSA Rapids Foodborne | C.

  22. Slide 22: Key Focus Activities

    Key Focus Activities Commercial excellence Product lifecycle management Operational efficiency Vision The health system’s (IDNs) trusted partner, spanning the continuum of care from the physician office to the hospital laboratory, delivering expertise and innovation in gastrointestinal disease testi

  23. Slide 23: Life Science Strategy

    Life Science Strategy ~

  24. Slide 24: Life Science Overview

    Life Science Overview FY18 Sales by Platform CORE ACTIVITIES Development Manufacturing Sales & Distribution CORE PRODUCTS Bulk Raw Materials Antigens Antibodies PCR/qPCR reagents Nucleotides Bioresearch reagents FY18 Sales by Region 24

  25. Slide 25: Life Science Strategic Summary

    Life Science Strategic Summary Leverage strong IA position in IVD and in China to grow MDx Leverage strong MDx position in academics to grow IA Top 200 focus – Broad offering across IA & MDx New Go To Market Resource Utilization Pivot sales focus to high value accounts R&D consolidation: Centers of

  26. Slide 26: Life Science Growth Drivers

    Life Science Growth Drivers $9,000 $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $- 2014 2015 2016 2017 2018 Immuno Reagents Molecular Reagents Continued penetration into growing China market ZIKA Virus New product penetration globally 26

  27. Slide 27: Life Science Revenues

    Life Science Revenues ($ millions) Planning for Low Double-digit Growth in 2019 $80 $70 $63 $60 $57 $51 $49 $50 $40 $30 $20 $10 $- 2015A 2016A 2017A 2018A 27

  28. Slide 28: Meridian Strategy Summary

    Meridian Strategy Summary COMPANY • New growth orientation • Focus resources on core target markets • Increase investment in R&D, acquisitions • Manage competitive pressures and product life cycles • Leverage cost structure and operational efficiency • Balance capital allocation priorities DIAGNOSTI

  29. Slide 29: Fourth Quarter and Full Year Fiscal 2018 Results

    Fourth Quarter and Full Year Fiscal 2018 Results meridian BIOSCIENCE~

Meridian Bioscience — FY2018 Earnings Presentation on 6ix